Please login to the form below

Not currently logged in
Email:
Password:

Xeljanz

This page shows the latest Xeljanz news and features for those working in and with pharma, biotech and healthcare.

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m

s Xeljanz (tofacitinib), Incyte/Eli Lilly’s Olumiant (baricitinib) and AbbVie’s upadacitinib.

Latest news

  • AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

    They think the drug could overtake Pfizer’s Xeljanz (tofacitinib), the first JAK inhibitor to reach the market for RA with sales of $1.35bn last year, but say this could ... Meanwhile, following the same path as Xeljanz, upadacitinib is also being

  • Pfizer’s Xeljanz picks up a third indication in IBD Pfizer’s Xeljanz picks up a third indication in IBD

    Pfizer’ s Xeljanz picks up a third indication in IBD. The JAK inhibitor can now treat US patients with ulcerative colitis. ... With the FDA approval of Xeljanz, adults living with moderately to severely active UC now have an oral option that may help

  • Pfizer’s Xeljanz picks up a third indication in the US Pfizer’s Xeljanz picks up a third indication in the US

    The JAK inhibitor can now treat patients with ulcerative colitis. The US Food and Drug Administration (FDA) has given its seal of approval to Pfizer’s Xeljanz (tofacitinib), a JAK inhibitor ... With the FDA approval of Xeljanz, adults living with

  • Pfizer’s flat sales focus investor attention on M&A Pfizer’s flat sales focus investor attention on M&A

    Once again, cancer drug Ibrance (palbociclib), anticoagulant Eliquis (apixaban) and Xeljanz (tofacitinib) for arthritis and other immunological indications led the charge, backed up by a solid advance for paediatric vaccine Prevnar

  • CHMP backs first-line use for AZ’s Tagrisso in lung cancer CHMP backs first-line use for AZ’s Tagrisso in lung cancer

    There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

More from news
Approximately 20 fully matching, plus 39 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

  • Infographic: RA Perceptions

    The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’ s Otezla (apremilast) and Pfizer’ s Xeljanz (tofacitinib), which both offer a new oral alternative ... Of the physicians who were familiar with

  • Brand leaders in RA will lose market share, predict rheumatologists

    JAK-inhibitors were the most commonly mentioned class, with Xeljanz the most frequently cited product. ... The EMA’ s refusal to grant a marketing authorisation for Xeljanz was disappointing for Pfizer, however, the drug is said to be performing in

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics